A flow cytometry facility for ocular regenerative medicine

这笔资金将建立伦敦大学学院眼科研究所的流式细胞术设施，以支持该研究所的眼睛再生医学计划。该研究所在提供新的眼病生物疗法，特别是干细胞疗法方面的卓越记录在国际上享有盛誉(例如，首例人类基因疗法、针对眼表疾病的干细胞疗法、针对晚期Stargardt‘s的干细胞疗法、针对老年性黄斑变性的干细胞疗法[AMD]按2013年目标)。拥有最先进的干细胞和祖细胞分析和分选设备的内部细胞仪设施将有助于保持伦敦大学学院眼科研究所作为世界领先的眼细胞移植中心的地位。

This funding will establish a UCL Institute of Ophthalmology flow cytometry facility to support the Institute's ocular regenerative medicine programme. The Institute is recognised internationally for its remarkably strong track record in delivery of novel biological therapies for eye disease and stem cell therapy in particular (e.g. first-in-man gene therapy, stem cell therapy for ocular surface disease, stem cell therapy for advanced Stargardt's, stem cell therapy for age-related macular degeneration [AMD] on target for 2013). An in-house cytometry facility with state-of-the-art equipment for analysis and sorting of stem and progenitor cells will to help to maintain UCL Institute of Ophthalmology as a world leading world centre for ocular cell transplantation.